Heska Announces Extension of Tri-Heart™ Plus Heartworm Preventive Agreement with Merck Animal Health

 Heska Announces Extension of Tri-Heart™ Plus Heartworm Preventive Agreement
                           with Merck Animal Health

Supply and License Agreement Amended and Extended through 2023

PR Newswire

LOVELAND, Colo., Dec. 12, 2013

LOVELAND, Colo., Dec. 12, 2013 /PRNewswire/ --Heska Corporation (NASDAQ:
HSKA, "Heska" or the "Company"), a leading provider of veterinary diagnostic
and specialty products, announced today that it has amended and extended its
Supply and License Agreement with Merck Animal Health related to the supply of
Heska's canine heartworm preventive. Merck Animal Health has the exclusive
right to market and sell Heska's canine heartworm preventive in the United
States and Canada.

Specific financial terms of the agreement were not disclosed. The agreement
calls for certain discounts for Merck Animal Health as well as annual
commitments to maintain exclusivity. In addition, Heska will receive payments
from Merck Animal Health related to the reimbursement of research &
development expenses as well as future milestone achievement.

"We are pleased to continue our relationship with one of the preeminent
companies in the animal health industry", Michael McGinley, Heska's President
of Pharmaceuticals and Biologicals commented. "We anticipate this agreement,
along with our recent product enhancements, will serve to increase our
production volume and ultimately, the market share our heartworm preventive is
able to obtain."

About Heska
Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic
and other specialty veterinary products. Heska's state-of-the-art offerings
to its customers include diagnostic instruments and supplies as well as single
use, point-of-care tests, pharmaceuticals and vaccines. The Company's core
focus is on the canine and feline markets where it strives to provide high
value products and unparalleled customer support to veterinarians. For
further information on Heska and its products, visit the company's website at

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future
financial and operating results. These statements are based on current
expectations and are subject to a number of risks and uncertainties. In
addition, factors that could affect the business and financial results of
Heska generally include the following: risks related to the performance and
actions of any third-party to which Heska has granted significant marketing
rights, including Merck Animal Health; uncertainties regarding Heska's ability
to achieve any development milestone; risks related to regulatory matters,
including the risk a regulatory agency may require Heska to reduce the time to
stated expiration of a product from time to manufacture; uncertainties related
to competition and the impact of actions of competitors; and the risks set
forth in Heska's filings and future filings with the Securities and Exchange
Commission, including those set forth in Heska's Quarterly Report on Form 10-Q
for the quarter ended September30,2013.

SOURCE Heska Corporation

Website: http://www.heska.com
Contact: At Heska Corporation: Jason Napolitano, Executive Vice President &
CFO, (970) 493-7272, Ext. 4105; or At Hayden IR: Brett Maas, Managing Partner,
(646) 536-7331, brett@haydenir.com
Press spacebar to pause and continue. Press esc to stop.